Simon Hubbert has stepped down from his position as chief executive officer on 18 April after serving in the role for more than six years. A search is underway for a successor and an announcement is expected in due course.
Hubbert joined Lombard during 2010 and was appointed CEO in 2011. During Hubbert’s tenure, Lombard achieved several significant milestones, including US FDA and Japan PMDA approval for Aorfix, its flagship product. In Japan, Aorfix now holds an approximate 8% market share. In 2014, Lombard consummated a NASDAQ IPO, and in 2015, acquired pre-revenue stage Altura Medical. Most recently, in December 2016, Lombard executed a strategic alliance with one of China’s largest medical devices companies, MicroPort Scientific Corporation.
“Simon made many significant contributions during his six years as CEO of Lombard including expanding the company’s product portfolio and geographic reach,” said Raymond W Cohen, chairman of the board of directors. “On behalf of the board and shareholders, we thank Simon for his contributions and diligent efforts during a time of significant change in the endovascular aneurysm repair market. We wish him well in his future endeavours.”
